Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company. If you are a reporter with a question about Regeneron, please call our Media Line at (914) 345-7800.
Webcast Regeneron Pharmaceuticals at Morgan Stanley 2008 Global Healthcare Unplugged Conference (Replay) Apr 30, 2008 at 1:40 p.m. ET
Regeneron Pharmaceuticals at Morgan Stanley 2008 Global Healthcare Unplugged Conference Wednesday, Apr 30, 2008 1:40 p.m. ET
For an e-mail response to questions about Regeneron, please contact us at media@regeneron.com.
Recent Press Releases
Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration - 05/08/08
-International study to evaluate efficacy and safety in treating a leading cause of blindness
Leverkusen, Germany, Montville, NJ and Tarrytown, NY, May 8, 2008 - Bayer HealthCare AG and
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the first patient has been
dosed in the VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF
Trap-Eye for the treatment of the neovascular form of Age-related Macular Degeneration (wet AMD), a
leading c... Full Article >>
Regeneron Reports First Quarter 2008 Financial and Operating Results - 05/01/08
TARRYTOWN, N.Y., May 01, 2008 (BUSINESS WIRE) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced
financial and operating results for the first quarter 2008. The
Company reported a net loss of $11.6 million, or $0.15 per share
(basic and diluted), for the first quarter of 2008 compared with a net
loss of $29.9 million, or $0.46 per share (basic and diluted), for the
first quarter of 2007.
At March 31, 2008, cash, restricted cash, and marketable
securities totaled $827.9 mill... Full Article >>
Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration - 04/28/08
Gains in visual acuity achieved in initial 12-week fixed dosing
phase of study maintained in PRN (as-needed) dosing phase
TARRYTOWN, N.Y. & LEVERKUSEN, Germany--(BUSINESS WIRE)--April 28,
2008--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer
HealthCare AG today announced that VEGF Trap-Eye dosed on a PRN
(as-needed) dosing schedule maintained the statistically significant
gain in visual acuity achieved after an initial, 12-week, fixed-dosing
phase of a Phas... Full Article >>
